Core Insights - The article highlights the significant growth in the domestic molecular interaction instrument market, with 248 units awarded in 2025, totaling approximately 529 million yuan, marking a year-on-year increase of 89.31% in quantity and 96.65% in value compared to 2024 [1][3]. Market Overview - The molecular interaction instruments are crucial for understanding biological interactions, which are fundamental to life sciences, biopharmaceuticals, and clinical medicine [2]. - The market trajectory from 2022 to 2025 shows a "first adjustment, then acceleration" pattern, with the number of awarded units increasing from 84 to 248, and the total value rising from 162 million yuan to 529 million yuan, indicating a nearly threefold expansion [3][4]. Brand Analysis - A total of 19 brands were analyzed, with 10 being imported brands and 9 domestic brands. Imported brands hold an 80% market share, while domestic brands have shown significant growth [4]. - The leading brands by awarded amount in 2025 were Cytiva (33.67%), Sartorius (14.75%), and NanoTemper (12.26%), collectively capturing over 60% of the market share [6]. Growth Drivers - The growth of the market is attributed to strong demand for SPR technology, which is considered the "gold standard" for molecular interaction research, alongside supportive government policies that boost procurement needs in research [9]. - Domestic brands like Gator Bio and Extreme Vision have shown remarkable growth rates of 262.35% and 652.32%, respectively, indicating a shift in market dynamics towards local manufacturers [10]. Technology Trends - The market remains dominated by SPR and BLI technologies, with SPR holding a 42.38% market share in 2025, up from 39.62% in 2024. BLI's share decreased to 21.83% [15]. - Emerging technologies such as MST and Spectral Shift collectively account for 12.76% of the market, indicating a diversification in technology applications [15]. Procurement Insights - The majority of procurement comes from universities, accounting for 66.13% of the total, followed by research institutions (14.11%) and hospitals (8.06%) [19]. - The price distribution shows a concentration in the mid-low price range, with the 1 million to 1.5 million yuan segment being the most prevalent, reflecting the budget constraints of academic and research institutions [22]. Regional Demand - The procurement distribution indicates that Beijing leads with 40 units purchased, followed by Shanghai with 20 units, and Liaoning and Zhejiang with 16 units each, highlighting the concentration of research resources in these areas [24]. Time Trends - There is a noticeable trend of procurement activity peaking towards the end of the year, particularly in December, which aligns with the budget execution cycles of research institutions [27].

进口品牌仍占主导，国产势力正加速崛起 在仪器品牌分析中，本次共统计到1 2个分子互作仪品牌，其中包括7家进口品牌： Cy ti v a（SPR技术，美国（产地为 瑞 典 ） ） 、 Sa r t o r ius （ BLI 技 术 +SPR 技 术 ， 德 国 ） 、 NanoTempe r （ MST 技 术 +Spe c t r a l Shift 技 术 ， 德 国 ） 、 Ma l v e rn Pana l y ti c a lITC 技 术 +GCI 技 术 ， 英 国 ） 、 TA （ ITC 技 术 ， 美 国 ） 、 LUMICKS （ Ce ll Av idit y 技 术 ， 荷 兰）和Pl a sme t r i x（SPR技术+LSPR技术，加拿大），以及Ga t o r Bi o（BLI技术）、量准（Me t aSPR技术）、极瞳 生命（SPR技术）、普芯生命（SPRi技术）和复拓（SPR技术） 5家国产品牌。 导读： 本次共统计到12个分子互作仪品牌，涉及131台仪器，中标总金额约2.69亿元。同比2023年，2024年分子互作仪中标数量与 中标总金额均实现了双位数高增长。 特别 ...